This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 45/6/1153    most recent 01.HYP.0000165677.71421.8cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shinoda, E. Search for Related Content PubMed PubMed Citation Articles by Shinoda, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Coronary Artery Disease Hazardous Substances DB ISOSORBIDE DINITRATE Related Collections Clinical Studies Coronary circulation Secondary prevention Coronary imaging: angiography/ultrasound/Doppler/CC Other arteriosclerosis Angiography

(Hypertension. 2005;45:1153.)
© 2005 American Heart Association, Inc.

Original Articles

Quantitative Coronary Angiogram Analysis

Nifedipine Retard Versus Angiotensin-Converting Enzyme Inhibitors (JMIC-B Side Arm Study)

Eiji Shinoda; Yoshiki Yui; Kazuhisa Kodama; Atsushi Hirayama; Hiroshi Nonogi; Kazuo Haze; Tetsuya Sumiyoshi; Saichi Hosoda; Chuichi Kawai for the Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group

From the Rakuyo Hospital (E.S.), Kyoto, Japan; Kyoto University Hospital (Y.Y.), Japan; Osaka Police Hospital (K.K., A.H.), Japan; National Cardiovascular Center (H.N.), Suita, Japan; Osaka City General Hospital (K.H.), Japan; The Sakakibara Heart Institute (T.S., S.H.), Tokyo, Japan; and Takeda General Hospital (C.K.), Kyoto, Japan.

Correspondence to Yoshiki Yui, MD, Department of Cardiovascular Medicine, Kyoto University Hospital, 54 Kawara-cho, Shogoin, Sakyo-Ku, Kyoto 606--8507, Japan. E-mail yoshiki{at}kuhp.kyoto-u.ac.jp

This study was performed to compare the effects of nifedipine retard and angiotensin-converting enzyme (ACE) inhibitors on the progression of coronary atherosclerosis by means of quantitative coronary angiogram. Coronary angiogram was performed before the start of the study and during the 3-year treatment period. This study was conducted on the assumption that possible coronary vasodilation, which may be caused by nifedipine, was excluded by administration of sufficient isosorbide dinitrate. The changes from the baseline in the minimum lumen diameter of the coronary artery in all measured segments were negligible in the nifedipine group (+0.02±0.27 mm; P=0.543), whereas they were significantly reduced in the ACE inhibitor group (–0.12±0.27 mm; P<0.001), with a significant difference observed between the groups (P=0.002). The number of progressors in the nifedipine group was significantly lower than that in the ACE inhibitor group (P=0.019), and there was also a significant difference between the groups in the number of patients in whom 1 lesion developed after treatment (P=0.040). However, the changes of minimum lumen diameter stratified by baseline percent diameter stenosis demonstrated that progression of coronary atherosclerosis was suppressed in the nifedipine group for lesions with a percent diameter stenosis of 40 but was suppressed in both groups for those with a percent diameter stenosis of 41. This study suggests that nifedipine retard and ACE inhibitors may be effective in suppression of progression of coronary atherosclerosis, and that nifedipine in particular may be effective for mild to moderate stenosis.

Key Words: nifedipine • angiotensin-converting enzyme • atherosclerosis